Sai Parenterals Limited submitted an investor presentation detailing Q1FY27 financial results and strategic updates in compliance with SEBI Listing Regulations Regulation 30.

Financial Performance - Q1FY27 (Consolidated)

  • Revenue from Operations: ₹178.7 crore (435.1% YoY growth, -9.7% QoQ)
  • Total Revenue: ₹182.4 crore (including Other Income of ₹3.7 crore)
  • Gross Profit: ₹76.2 crore with Gross Profit Margin of 41.8% (improved from 38.1% in Q4FY26)
  • EBITDA: ₹27.3 crore with EBITDA Margin of 14.9% (improved from 14.4% in Q4FY26)
  • Profit After Tax: ₹7.9 crore with PAT Margin of 4.3%
  • The company achieved approximately 24% of its FY27 revenue target of ₹750 crore in Q1

Strategic Acquisitions Proposed

The Board has approved variation in utilization of IPO proceeds for two strategic acquisitions (subject to shareholder approval):

Saicriti Pharma Private Limited Acquisition (60% stake)

  • Investment: ₹83.83 crore from IPO proceeds
  • Business: Critical-care injectable facility under construction at Gummadidala, Hyderabad
  • Capacity: ~154.66 million units (47% higher than original expansion plan)
  • Total Project Cost: ₹215 crore
  • Funding Structure: 40% equity (₹55.89 cr) from Saicriti promoters, ₹75.24 crore project debt
  • Target Completion: April 2027
  • Residual 40%: To be acquired after 3 years at 12x trailing earnings

Prathyak Laboratories Private Limited Acquisition (60% stake)

  • Investment: ₹15 crore from IPO proceeds
  • Business: Operating R&D centre at Genome Valley, Hyderabad
  • Capabilities: 28 scientists, 150 SKUs across 86 molecules, complex injectables and oncology
  • Target Completion: On or before 30th September 2026
  • Residual 40%: To be acquired within 2 years at same valuation (~₹12 crore)

Manufacturing Capacity and Expansion

Current Manufacturing Footprint:

  • Unit I (Jeedimetla): 42 mn units injectables (to be discontinued)
  • Unit II (Jeedimetla): 15 mn units sterile penicillin (to be discontinued)
  • Unit III (Bhongir): 240 mn units oral solids (expanding to 451 mn by Oct 2026)
  • Unit IV (Bollaram): 293 mn units cephalosporin
  • Revat Unit (Ongole): 570 mn units oral solids
  • Total Indian manufacturing area: 1,14,540 sq ft

Capacity Utilization Trends:

  • Unit II: 95% in H1FY26
  • Unit III: Scaled from 24.77% in FY23 to 87% in H1FY26
  • Overall group utilization: Improved across facilities

Australia Facility (Noumed):

  • Total Capex: AUD 53 million (₹311 crore)
  • Invested to date: AUD 40 million
  • Government Grant: AUD 20 million received
  • Target Completion: January 2027
  • TGA Inspection: Expected by 31 March 2027
  • Manufacturing Start: Phase 1 targeted from April 2027

Business Verticals Performance

Two Business Verticals:

1. Branded Generic Formulations: 37% of FY26 net revenue, 15.6% CAGR FY23-FY26

2. CDMO Products & Services: 63% of FY26 net revenue, 355.6% CAGR FY23-FY26

Export Revenue Mix:

Significant growth in export contribution from 3% of revenue in FY23 to 63% in FY26

Regulatory and Accreditation Status

  • New Saicriti facility being built to USFDA standard with EU-GMP, WHO-GMP and PIC/S targets
  • Accreditation expected within twelve months of physical completion
  • Revenue impact: South-East Asia, Middle East and Latin America from FY28; European Union from FY29

R&D Capabilities

  • SP Analytics: Dedicated R&D subsidiary
  • Current: 34 personnel at Unit III formulation R&D facility
  • Pipeline: 55 dossiers developed in-house, 45 approved by Philippines FDA
  • Future: 67 dossiers under development for FY27-28

Guidance and Outlook

  • FY27 Revenue Target: ₹750 crore
  • FY27 EBITDA Margin Target: ~17% (from 14.9% in Q1FY27)
  • Growth expected to be H2-weighted due to pricing benefits and new facility commissioning
  • FY28 expected to be inflection point as investments monetize

Capital Expenditure Programme

  • Total programme: ₹571 crore at group level
  • Company's funded share: ₹440 crore (unchanged from original plan)
  • Includes: Saicriti facility (₹215 cr), Units III and IV upgrades (₹27 cr), Prathyak acquisition (₹15 cr), Adelaide facility (₹311 cr)

Management Commentary

Anil Kumar Karusala, Chairman and Managing Director, stated that Q1FY27 marked a solid start to the year with revenue representing approximately 24% of FY27 target. Gross margin improved to 41.8% reflecting initial benefits of negotiated price revisions, with further benefits expected in Q2. The company continues to execute on strategic growth initiatives with the proposed acquisitions strengthening injectable manufacturing capacity and R&D capabilities.

Corporate Actions

  • US market entry under evaluation with Board approval for incorporation of US subsidiary
  • Variation in objects of IPO issue approved by Board, subject to shareholders' approval